These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 795805)

  • 1. [Trial of Bilopaque, a new contrast medium for oral cholecystography].
    Magos E; Delhaye J; Dejong M
    J Belge Radiol; 1976; 59(4):369-76. PubMed ID: 795805
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial of bilopaque (tyropanoate sodium) oral cholecystography. Evaluation of time for the optimal and peak opacification of the gallbladder.
    Han SY; Witten DM
    Radiology; 1974 Sep; 112(3):529-30. PubMed ID: 4843280
    [No Abstract]   [Full Text] [Related]  

  • 3. The biliary and urinary excretion of sodium tyropanoate and sodium ipodate in dogs: pharmacokinetics, influence of bile salts and choleretic effects with comparison to iopanoic acid.
    Berk RN; Loeb PM; Cobo-Frenkel A; Barnhart JL
    Invest Radiol; 1977; 12(1):85-95. PubMed ID: 838560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative evaluation of a new oral cholecystographic agent bilopaque with orabilex.
    JUDKINS MP BILLIMORIA PE; DOTTER CT
    Am J Roentgenol Radium Ther Nucl Med; 1963 Apr; 89():859-63. PubMed ID: 14042043
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical comparison of tyropanoate sodium, ipodate sodium, and iopanoic acid.
    Russell JG; Frederick PR
    Radiology; 1974 Sep; 112(3):519-23. PubMed ID: 4843279
    [No Abstract]   [Full Text] [Related]  

  • 6. Conjugated sodium tyropanoate (Bilopaque) in the bowel: significance of its presence or absence after first-dose oral cholecystography.
    Muhletaler CA; Gerlock AJ; Avant GR
    Radiology; 1981 Nov; 141(2):311-6. PubMed ID: 7291552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of diet and fasting on gallbladder opacification during oral cholecystography in dogs as measured by computed tomography.
    Fon GT; Hunter TB; Berk RN; Capp MP
    Radiology; 1980 Sep; 136(3):585-92. PubMed ID: 7403534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral cholecystography in the early phase of acute alcoholic pancreatitis. A prospective, randomized comparison of Telepaque and Bilopaque.
    Smith HJ; Corbett DB; Loeb PM; Peterson WL
    Invest Radiol; 1982; 17(6):629-33. PubMed ID: 6759457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time of optimal gallbladder opacification with bilopaque (tyropanoate sodium).
    Oliphant M; Whalen JP; Evans JA
    Radiology; 1974 Sep; 112(3):531-2. PubMed ID: 4843281
    [No Abstract]   [Full Text] [Related]  

  • 10. TYROPANOATE SODIUM. A NEW ORAL CHOLECYSTOGRAPHIC MEDIUM.
    DAVIS JJ
    Rocky Mt Med J; 1964 Apr; 61():35-9. PubMed ID: 14137928
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the opacifying characteristics and pharmacologic responses of iocetamic acid (Cholebrine), a new oral cholecystographic agent, with sodium tyropanoate (Bilopaque).
    Wishart DL; Dotter CT
    Am J Roentgenol Radium Ther Nucl Med; 1973 Oct; 119(2):429-32. PubMed ID: 4748234
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiographic appearance of the nonabsorbed (unconjugated) and conjugated sodium tyropanoate (Bilopaque) in the bowel.
    Muhletaler CA; Gerlock AJ; Amberg JR; Avant GR
    Invest Radiol; 1982; 17(5):506-9. PubMed ID: 7141832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BILOPAQUE: A NEW CHOLECYSTOGRAPHIC MEDIUM.
    BURHENNE HJ
    Radiology; 1963 Oct; 81():629-31. PubMed ID: 14078329
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of hepatic binding of thyroxine by cholecystographic agents.
    Felicetta JV; Green WL; Nelp WB
    J Clin Invest; 1980 May; 65(5):1032-40. PubMed ID: 7364937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyropanoate cholecystography early in the course of acute pancreatitis.
    Longstreth GF; Slivka J
    J Clin Gastroenterol; 1981; 3 Suppl 1():47-50. PubMed ID: 7328298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary clinical evaluation of a new cholecystographic medium, bilopaque.
    BENISEK GJ; GUNN JA
    Am J Roentgenol Radium Ther Nucl Med; 1962 Oct; 88():792-6. PubMed ID: 13867240
    [No Abstract]   [Full Text] [Related]  

  • 17. The choleretic action of sodium tyropanoate (bilopaque sodium) in the dog: preliminary observation.
    Nelson JA; Straubus AE; Amberg JR
    Invest Radiol; 1974; 9(6):438-43. PubMed ID: 4430583
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical evaluation of a new cholecystographic agent: WIN 8851-2 (Bilopaque).
    POLLACK S
    J Okla State Med Assoc; 1963 Jan; 56():13-7. PubMed ID: 13971989
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatic excretion of cholecystopaques introduced into the canine jejunum.
    Menuck L; Amberg JR; Bates M
    Invest Radiol; 1977; 12(1):106-8. PubMed ID: 138663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyropanoate cholecystography and reversible renal failure.
    Fisher MS
    JAMA; 1975 Nov; 234(7):743. PubMed ID: 1242457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.